PharmaZee: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://pharmazee.co, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   ““clinically proven medications””

2. 2

   ““proven prescription medications””

3. 3

   ““Same active ingredient as Ozempic® and Wegovy®””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

pharmazee.co returned a live storefront when we checked in August 2026, covering GLP-1 weight loss plus longevity, hair-loss, anti-ageing and sexual-health lines with discreet delivery. We did not review every page on the site.

"Proven" is a strong word carrying no information, which is why it turns up twice here. A proven medication implies someone ran a study, on something, and reached a result — but the phrase as quoted names no trial, no endpoint and no product, so there is nothing a reader can check. FDA's objection is that the word transfers the credibility of the approved brand's evidence onto a compounded preparation that was not part of it. Notice what is absent from this letter: no price claim, no dosing claim, no safety finding, and no suggestion the medication does not work. For a shopper the practical move is to treat "proven" and "clinically proven" as design elements rather than data. If a page wants to convince you on evidence, it can name the trial; if it only offers the adjective, price the product as what it is — a compounded preparation — and judge the cost against compounded competitors rather than against the brand.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence PharmaZee failed to respond.